
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABTT34 | BM&FBovespa | BRL | Delayed | |
ABT | NYSE | USD | Real-time | |
0Q15 | London | USD | Real-time | |
ABT | Mexico | MXN | Delayed | |
ABT | Switzerland | CHF | Delayed | |
ABT | Frankfurt | EUR | Delayed | |
ABT | Xetra | EUR | Delayed | |
ABT | TradeGate | EUR | Delayed | |
ABTCL | Santiago | CLP | Delayed | |
ABT | Santiago | USD | Delayed | |
ABT | Buenos Aires | ARS | Delayed | |
ABT-RM | Moscow | RUB | Real-time |
For the three months ended 31 March 2022, Abbott Laboratories revenues increased 14% to $11.9B. Net income increased 36% to $2.45B. Revenues reflect Diagnostics Products segment increase of 32% to $5.29B, Medical Devices segment increase of 7% to $3.57B, Established Pharmaceutical Products segment increase of 7% to $1.15B, United States segment increase of 29% to $4.94B, All other Countries segment increase of 5% to $6.96B.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 11895 | 11468 | 10928 | 10223 |
Gross Profit | 6908 | 6748 | 6505 | 5276 |
Operating Income | 2912 | 2378 | 2546 | 1392 |
Net Income | 2447 | 1989 | 2100 | 1189 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 74007 | 75196 | 73795 | 73269 |
Total Liabilities | 38608 | 39394 | 39373 | 39469 |
Total Equity | 35399 | 35802 | 34422 | 33800 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 2065 | 10533 | 7466 | 4765 |
Cash From Investing Activities | -360 | -2008 | -1337 | -686 |
Cash From Financing Activities | -3823 | -5494 | -3608 | -2231 |
Net Change in Cash | -2124 | 2961 | 2464 | 1820 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review